Pomalidomide in heavily pretreated refractory multiple myeloma: a case report. (February 2017)

• Record Type: Journal Article
• Authors: Palmas, Angelo; Piras, Giovanna; Uras, Antonella; Asproni, Rosanna; Murineddu, Marco; Monne, Maria; Stradoni, Roberta; Latte, Giancarlo
• Is Part Of: Future oncology. Volume 13(2017)Supplement 5
• Page Start: 7
• Page End: 9
• Publication Date: 2017-02
• Subjects: complete response -- drug resistance -- immunomodulatory drug -- pomalidomide -- refractory multiple myeloma -- relapsed multiple myeloma; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0460
• Languages: English
• ISSNs: 1479-6694

Abstract

We present the case of a 70-year-old man diagnosed with multiple myeloma in 2008, who after four therapy lines initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1–21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally). The patient was treated with pomalidomide for almost 2 years achieving a complete remission after 12 cycles. Complete remission was maintained for 9 months. This case illustrates the potential of pomalidomide plus low-dose dexamethasone to overcome multiple myeloma refractoriness inducing a quick and very prolonged remission.